Get the Stockscreener App
1.11
1.77%
-0.02
After Hours:
1.11
Oncolytics Biotech, Inc. stock is currently priced at $1.11, with a 24-hour trading volume of 285.54K.
It has seen a -1.77% decreased in the last 24 hours and a +6.73% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.15 pivot point. If it approaches the $1.10 support level, significant changes may occur.
Previous Close:
$1.13
Open:
$1.15
24h Volume:
285.54K
Market Cap:
$83.72M
Revenue:
-
Net Income/Loss:
$-20.59M
P/E Ratio:
-3.3154
EPS:
-0.3348
Net Cash Flow:
$-17.99M
1W Performance:
-5.13%
1M Performance:
+6.73%
6M Performance:
-26.00%
1Y Performance:
-28.85%
1D Range:
$1.10
$1.15
52W Range:
$0.883
$3.3942
Oncolytics Biotech, Inc. Stock (ONCY) Company Profile
Name
Oncolytics Biotech, Inc.
Sector
Industry
Phone
403-670-7377
Address
210, 1167 Kensington Crescent NW, Calgary, AB
Oncolytics Biotech, Inc. Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech, Inc. Stock (ONCY) Latest News
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments - Baystreet.ca
Baystreet.ca
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments - Baystreet.ca
Baystreet.ca
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference - The Globe and Mail
The Globe and Mail
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb - The Globe and Mail
The Globe and Mail
Brokers Offer Predictions for Oncolytics Biotech Inc.'s FY2024 Earnings (TSE:ONC) - Defense World
Defense World
Raymond James Equities Analysts Raise Earnings Estimates for Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Defense World
Oncolytics Biotech, Inc. Stock (ONCY) Financials Data
Oncolytics Biotech, Inc. (ONCY) Net Income 2024
ONCY net income (TTM) was -$20.59 million for the quarter ending December 31, 2023, a -8.29% decrease year-over-year.
Oncolytics Biotech, Inc. (ONCY) Cash Flow 2024
ONCY recorded a free cash flow (TTM) of -$17.99 million for the quarter ending December 31, 2022, a +0.70% increase year-over-year.
Oncolytics Biotech, Inc. (ONCY) Earnings per Share 2024
ONCY earnings per share (TTM) was -$0.3046 for the quarter ending December 31, 2023, a +9.56% growth year-over-year.
About Oncolytics Biotech, Inc.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
0.77%
1.20%
Cap:
|
Volume (24h):